作者
Peter Ueda, Henrik Svanström, Mads Melbye, Björn Eliasson, Ann-Marie Svensson, Stefan Franzén, Soffia Gudbjörnsdottir, Kristian Hveem, Christian Jonasson, Björn Pasternak
发表日期
2018/11/14
期刊
bmj
卷号
363
出版商
British Medical Journal Publishing Group
简介
Objective
To assess the association between the use of sodium glucose cotransporter 2 (SGLT2) inhibitors and seven serious adverse events of current concern.
Design
Register based cohort study.
Setting
Sweden and Denmark from July 2013 to December 2016.
Participants
A propensity score matched cohort of 17 213 new users of SGLT2 inhibitors (dapagliflozin, 61%; empagliflozin, 38%; canagliflozin, 1%) and 17 213 new users of the active comparator, glucagon-like peptide 1 (GLP1) receptor agonists.
Main outcome measures
The primary outcomes were lower limb amputation, bone fracture, diabetic ketoacidosis, acute kidney injury, serious urinary tract infection, venous thromboembolism, and acute pancreatitis, as identified from hospital records. Hazard ratios and 95% confidence intervals were estimated by using Cox proportional hazards models.
Results
Use of SGLT2 inhibitors, as compared with GLP1 …
学术搜索中的文章
P Ueda, H Svanström, M Melbye, B Eliasson… - bmj, 2018